학술논문

Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)
Document Type
Journal
Source
ANNALS OF ONCOLOGY; SEP 2017, 28 2p. Supplement: 5
Subject
Language
English
ISSN
15698041